KKR & Co. Inc. (KKR)

NYSE - Nasdaq Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

52.03

+1.09

(+2.14%)

As of 10:12AM EDT. Market open.

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bearishpattern detected

Momentum

View all chart patterns

Performance Outlook

Previous Close	50.94
Open	52.44
Bid	52.47 x 900
Ask	52.53 x 900
Day's Range	52.03 - 52.96
52 Week Range	47.51 - 83.90
Volume	542,536
Avg. Volume	3,988,170

Market Cap	44.366B
Beta (5Y Monthly)	1.48
PE Ratio (TTM)	7.11
EPS (TTM)	7.31
Earnings Date	Aug 01, 2022 - Aug 05, 2022
Forward Dividend & Yield	0.62 (1.22%)
Ex-Dividend Date	May 13, 2022
1y Target Est	79.46

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for KKR

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

KKR & Co. Inc.
Market Digest: AMGN, CHKP, KLAC, MAR, X, KKR, TWTR, QSR, CC, TDOCApril Deluge: Our Monthly Survey of the Economy, Interest Rates, and Markets
Rating
Fair Value
Economic Moat
12 days agoArgus Research

All

News

Press Releases

Research Reports

PR Newswire
Ampersand-backed Alliance Pharma to acquire LGC's Drug Development Solutions Business ("DDS") and welcomes KKR as joint shareholder
Alliance Pharma, a US-based Bioanalytical CRO and an Ampersand portfolio company, has agreed to acquire DDS, a UK-based Bioanalytical Business Unit of LGC. KKR will become an equal shareholder in the combined business alongside Ampersand Capital Partners. Backed by Ampersand and KKR, Alliance and DDS plan to expand the company's geographic reach, broaden its laboratory capabilities and expand its service portfolio. The transaction is subject to regulatory approvals and expected to be completed i
Bloomberg
Nucor Slides After Announcing Door Maker Acqusition From KKR
(Bloomberg) -- Shares of Nucor Corp. fell to a three-month low after the company said it will buy a garage doors maker from KKR & Co. in a deal valued at $3 billion.Most Read from BloombergMeet the Hedge-Fund Manager Who Warned of Terra’s $60 Billion ImplosionOmicron Is Turning Out to Be a Weak VaccineU.S. Stocks Extend Losses in Late Session Selloff: Markets WrapGoldman’s Blankfein Says US at 'Very, Very High Risk' of RecessionOne-Time Richest Singapore Tycoon Has Lost 80% of His FortuneAfter a
- Stock Markets Are Overpricing Recession Risk, JPMorgan Strategist Says
  Bloomberg
- Wheat Surges Amid Fears of Shortages as India Restricts Exports
  Bloomberg
Business Wire
KKR and C.H.I. Employees Prove ‘Ownership Works’ With Sale of C.H.I. Overhead Doors to Nucor
NEW YORK & ARTHUR, Ill., May 16, 2022--KKR, a leading global investment firm, today announced the signing of an agreement to sell C.H.I. Overhead Doors ("C.H.I." or "the Company"), a leader in the garage door industry, to Nucor Corporation in a transaction valued at $3.0 billion. The sale will represent one of KKR’s largest returns in recent history, at 10 times the original equity invested, inclusive of distributions. All C.H.I. employees will receive a substantial cash payout on their equity i
- Nucor to acquire C.H.I. Overhead Doors from KKR in deal valued at $3 billion
  MarketWatch
- KKR to Sell C.H.I. Overhead, Making 10 Times Its Money
  Barrons.com